针对多发性骨髓瘤中免疫效应细胞相关血液毒性的干细胞增强:最大限度地减少长期并发症,并扩大后CAR T细胞疗法复发选择
Meera Mohan1, Carolina Schinke2
1Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
Expert review of hematology
|October 4, 2025
概括
免疫效应细胞相关血毒性 (ICAHT) 是CAR T细胞治疗后的常见挑战. 干细胞增强 (SCB) 可以有效地管理长期的ICAHT,改善患者的治疗结果,并使未来的治疗选择成为可能.
科学领域:
- 血液学 血液学 血液学
- 免疫治疗是一种免疫疗法.
- 在瘤学瘤学.
背景情况:
- 细胞衰竭是BCMA CAR T细胞治疗复发性多发性骨髓瘤 (MM) 后的常见不良事件.
- 免疫效应细胞相关血液毒性 (ICAHT) 描述了来自CAR T细胞疗法的独特血液毒性.
- 长时间的ICAHT (>30天) 带来了管理挑战,包括感染,输血需求和非复发性死亡率的增加.
研究的目的:
- 审查有关ICAHT的当前数据.
- 确定干细胞提升 (SCB) 如何改善ICAHT的结果.
- 提供对SCB未来应用的见解.
主要方法:
- 关于"CAR-T"",ICAHT"和"干细胞"的文献评论 在PubMed.
- 分析现有数据和精选的引用.
主要成果:
- 在长时间的ICAHT中,SCB可以导致迅速而持久的计数恢复.
- SCB可以最大限度地减少与ICAHT相关的长期并发症.
- 在CAR后的T细胞治疗复发环境中,SCB可以促进治疗选择.
结论:
- SCB改善了长期ICAHT的发病率和潜在死亡率.
- 未来的SCB使用取决于前几行中长期的CAR T细胞治疗结果.
- 预防性干细胞采集应考虑在患有ICAHT高风险的患者.
更多相关视频
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
3.7K
12:55Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
22.0K
相关概念视频
Stem Cell Therapy for Tissue Regeneration
4.6K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.6K
Bone Marrow Sampling and Transplants
881
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
881
Multipotency of Hematopoietic Stem Cells
3.8K
The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
3.8K
Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Regulation of Hematopoietic Stem Cells
4.0K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
4.0K
